The phase 3 SARC041 trial established CDK4-inhibition as an effective targeted therapy option for recurrent/metastatic dedifferentiated liposarcoma, a disease with universal CDk4-expression and virtually no other effective systemic treatment option, where abemaciclib nearly halved rate of death (HR 0.55) when given at time of enrollment versus at further progression. | Dickson, ASCO 2026
